Michael W. Flanagan
Chief Scientific Officer; Director · 4 filings · Latest: Sep 18, 2026
Atrium Therapeutics, Inc.
Avidity Biosciences, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
RNA | Michael W. Flanagan | Chief Scientific Officer | Jan 21, 2026 | Sale | $72.45 | 6,534 | $473.4K | 85,093 | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Sep 11, 2025 | Proposed Sale | $46.40 | 20,000 | $928.0K | — | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Jun 11, 2025 | Proposed Sale | $33.62 | 20,000 | $672.4K | — | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Mar 11, 2025 | Proposed Sale | $30.04 | 20,000 | $600.8K | — | |
RNA | W. MICHAEL FLANAGAN | — | Dec 11, 2024 | Proposed Sale | $36.10 | 24,000 | $866.4K | — | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Oct 1, 2024 | Proposed Sale | $45.93 | 38,018 | $1.7M | — | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Sep 23, 2024 | Proposed Sale | $44.48 | 36,329 | $1.6M | — | |
RNA | WILLIAM MICHAEL FLANAGAN | — | Sep 11, 2024 | Proposed Sale | $40.79 | 111,394 | $4.5M | — |